文献速递妇科

COVID-19大流行第一年的妇科癌症诊疗

Gynecologic cancer care in the first year of the COVID-19 pandemic.
PubMed 文献 · Gynecol Oncol · 2023-10-19

基于美国国家癌症数据库2017-2020年数据,分析COVID-19大流行第一年妇科癌症诊断与治疗启动的影响。2020年妇科癌症诊断率比为0.90(95%CI 0.90-0.91),COVID-19诊断与治疗延迟相关(aOR 1.50,95%CI 1.35-1.67)。

要点

  • 2020年妇科癌症诊断率较2017-2019年下降,率比0.90(95%CI 0.90-0.91)。
  • 2020年诊断遗漏或延迟风险增加的因素包括宫颈癌、较早分期、较年轻年龄、较低合并症水平及缺乏医疗保险。
  • COVID-19诊断与治疗延迟相关(aOR 1.50,95%CI 1.35-1.67),倾向评分匹配后风险仍显著升高。

核心结论

  • COVID-19大流行第一年妇科癌症诊断和及时诊疗受到负面影响,某些亚组风险更高。

研究设计与样本

  • 纳入国家癌症数据库2017-2020年诊断为妇科癌症的患者。
  • 计算发病率比以比较COVID-19大流行第一年与前三年的妇科癌症诊断。
  • 比较出现8周治疗延迟与未延迟的患者,采用多因素logistic回归识别与治疗延迟相关的因素。
  • 利用倾向评分分析比较诊断为COVID-19与未诊断COVID-19患者的癌症治疗延迟率。

主要发现

  • 2020年与2017-2019年相比,诊断为妇科癌症的发病率比为0.90(95%CI 0.90-0.91)。
  • 2020年诊断遗漏或延迟风险增加的因素包括宫颈癌、较早癌症分期、较年轻年龄、较低医疗合并症水平及缺乏医疗保险。
  • 2020年与治疗延迟相关的因素包括COVID-19诊断(aOR 1.50,95%CI 1.35-1.67),以及种族和民族、保险类型、合并症、癌症分期和原发部位。
  • 倾向评分匹配后,诊断为COVID-19的患者治疗延迟风险仍显著升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the impact of the early COVID-19 pandemic on the diagnosis and initiation of treatment for patients with gynecologic cancer. METHODS: Patients diagnosed with gynecologic cancer in the National Cancer Database during 2017-2020 were included. For the first aim, incidence rate ratios were calculated to compare gynecologic cancer diagnosis in the first year of the COVID-19 pandemic to the three years prior, and factors associated with a reduction in diagnosis were identified. For the second aim, patients who experienced an 8-week delay in cancer treatment were compared to those who did not. Multivariate logistic regression was used to identify factors associated with treatment delay. Propensity score analysis was utilized to compare the rate of cancer treatment delay in patients who were diagnosed with COVID-19 to those who were not. RESULTS: The incidence rate ratio of being diagnosed with gynecologic cancer in 2020 versus 2017-2019 was 0.90 (95%CI 0.90-0.91). Factors associated with increased risk of missed or delayed diagnosis in 2020 included cervical cancer, earlier cancer stage, younger age, lower levels of medical comorbidity, and lack of health insurance. In 2020, factors associated with treatment delay included COVID-19 diagnosis (aOR 1.50, 95%CI 1.35-1.67), in addition to race and ethnicity, insurance type, comorbidity, cancer stage, and primary site. The risk of treatment delay remained significantly elevated in patients diagnosed with COVID-19 after propensity-score matching. CONCLUSIONS: Gynecologic cancer diagnosis and timely provision of care were negatively impacted during the first year of the COVID-19 pandemic, with certain subgroups at elevated risk.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chapman GC, Smrz SA, Gordon JC, et al. Gynecologic cancer care in the first year of the COVID-19 pandemic. Gynecol Oncol. 2023. PMID: 37862793. doi:10.1016/j.ygyno.2023.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。